JAMP DESVENLAFAXINE DIN 02495147
Status: Marketed
Holder: JAMP PHARMA CORPORATION
Available to quote
Health Canada record
| Active ingredient(s) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG |
|---|---|
| Dosage form | Tablet (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N06AX23 DESVENLAFAXINE |
| Original market date | 14-Feb-2022 |
| Current status date | 14-Feb-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02525623 | AG-DESVENLAFAXINE | ANGITA PHARMA INC. | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG | Marketed |
| 02525615 | AG-DESVENLAFAXINE | ANGITA PHARMA INC. | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG | Marketed |
| 02469847 | INTELLI-DESVENLAFAXINE | INTELLIPHARMACEUTICS CORP | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG | Approved |
| 02469855 | INTELLI-DESVENLAFAXINE | INTELLIPHARMACEUTICS CORP | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG | Approved |
| 02495139 | JAMP DESVENLAFAXINE | JAMP PHARMA CORPORATION | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG | Marketed |
| 02321106 | PRISTIQ | PFIZER CANADA ULC | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG | Marketed |
| 02321092 | PRISTIQ | PFIZER CANADA ULC | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG | Marketed |
| 02532166 | SPC-DESVENLAFAXINE | SUN PHARMA CANADA INC | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG | Marketed |
| 02532158 | SPC-DESVENLAFAXINE | SUN PHARMA CANADA INC | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG | Marketed |
| 02458217 | TEVA-DESVENLAFAXINE | TEVA CANADA LIMITED | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG | Marketed |
| 02458225 | TEVA-DESVENLAFAXINE | TEVA CANADA LIMITED | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG | Marketed |
| 02467119 | APO-DESVENLAFAXINE EXTENDED-RELEASE TABLETS | APOTEX INC | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG | Dormant |
| 02467127 | APO-DESVENLAFAXINE EXTENDED-RELEASE TABLETS | APOTEX INC | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG | Dormant |
| 02441667 | GD-DESVENLAFAXINE | GENMED A DIVISION OF PFIZER CANADA ULC | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG | Cancelled Pre Market |
| 02441675 | GD-DESVENLAFAXINE | GENMED A DIVISION OF PFIZER CANADA ULC | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG | Cancelled Pre Market |
| 02526913 | PRO-DESVENLAFAXINE | PRO DOC LIMITEE | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG | Cancelled Post Market |
| 02526921 | PRO-DESVENLAFAXINE | PRO DOC LIMITEE | Tablet (Extended-Release) | DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 27580 | 2022-02-14 | Abbreviated New Drug Submission (ANDS) |